Edition:
United States

Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

9.40USD
14 Jun 2019
Change (% chg)

$-0.56 (-5.62%)
Prev Close
$9.96
Open
$9.98
Day's High
$9.98
Day's Low
$9.37
Volume
110,005
Avg. Vol
111,444
52-wk High
$15.91
52-wk Low
$8.66

Latest Key Developments (Source: Significant Developments)

Prothena Reports Results From The Phase 3 Vital Amyloidosis Study Of Neod001 In Al Amyloidosis
Thursday, 18 Apr 2019 04:05pm EDT 

April 18 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS RESULTS FROM THE PHASE 3 VITAL AMYLOIDOSIS STUDY OF NEOD001 (BIRTAMIMAB) IN AL AMYLOIDOSIS.PROTHENA - RESULTS FROM FINAL ANALYSIS OF COMPOSITE PRIMARY ENDPOINT WERE CONSISTENT WITH FUTILITY ANALYSIS REPORTED IN APRIL 2018 FROM PHASE 3 VITAL STUDY.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES TO ADVANCE NEOD001.PROTHENA CORPORATION PLC - NONE OF SECONDARY ENDPOINTS ACHIEVED STATISTICAL SIGNIFICANCE IN TOTAL STUDY POPULATION OF PHASE 3 VITAL STUDY.PROTHENA CORPORATION PLC - NEOD001 AND CONTROL ARMS HAD SIMILAR FREQUENCIES OF TREATMENT EMERGENT ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS.  Full Article

Prothena Corporation Q4 Loss Per Share $0.56
Thursday, 14 Feb 2019 04:05pm EST 

Prothena Corporation Plc ::PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE.Q4 LOSS PER SHARE $0.56.Q4 EARNINGS PER SHARE ESTIMATE $-0.94 -- REFINITIV IBES DATA.EXPECTS FULL YEAR 2019 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $64 MILLION TO $72 MILLION.QUARTER-END CASH AND RESTRICTED CASH POSITION OF $431.7 MILLION PROVIDES FUNDING TO ADVANCE NEUROSCIENCE PIPELINE.ENTERED INTO GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE.  Full Article

Prothena Sees $9 Mln-$13 Mln Restructuring Charges In Q2
Friday, 25 May 2018 04:41pm EDT 

May 25 (Reuters) - Prothena Corporation PLC ::PROTHENA CORP SAYS $9 MILLION-$13 MILLION RESTRUCTURING CHARGES RELATED TO WORKFORCE REDUCTION EXPECTED TO BE INCURRED IN Q2 2018 - SEC FILING.  Full Article

Prothena Announces Reorganization To Focus Resources On Advancing Neuroscience Pipeline
Thursday, 24 May 2018 09:00am EDT 

May 24 (Reuters) - Prothena Corporation PLC ::PROTHENA ANNOUNCES REORGANIZATION TO FOCUS RESOURCES ON ADVANCING NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - INITIATED A REORGANIZATION TO ALIGN ITS RESOURCES ON ADVANCING ITS BROAD NEUROSCIENCE PIPELINE.PROTHENA CORPORATION PLC - FOLLOWING REORGANIZATION EXPECTS ITS WORKFORCE TO BE APPROXIMATELY 63 POSITIONS..PROTHENA CORPORATION PLC - COMPANY IS REVISING ITS FULL YEAR 2018 FINANCIAL GUIDANCE.PROTHENA CORPORATION PLC - EXPECTS 2018 NET CASH BURN FROM OPERATING & INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.PROTHENA CORPORATION PLC - AS A RESULT OF DISCONTINUATION OF NEOD001 DEVELOPMENT PROGRAM, WILL REDUCE WORKFORCE BY ABOUT 57 PERCENT.PROTHENA - ESTIMATED 2018 NET LOSS INCLUDES $80 TO $85 MILLION OF OPERATING EXPENSES ASSOCIATED WITH NEOD001 AND REORGANIZATION.PROTHENA - REORGANIZATION INCLUDES ONGOING CLINICAL-STAGE PROGRAMS FOR PRX002/RG7935, PROPRIETARY PROGRAM PRX004 DISCOVERY-STAGE PIPELINE.PROTHENA - REORGANIZATION INCLUDES DISCOVERY-STAGE PIPELINE, 3 PROGRAMS BEING ADVANCED UNDER COLLABORATION WITH CELGENE.  Full Article

Prothena reports Q3 loss per share $1.37
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Prothena Corporation Plc ::Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports third quarter financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Prothena Corporation Plc :Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article